In multiple myeloma treatment, for example, degradation of the zinc-finger transcription factors IKZF1 and IKZF3 accounts for the anti-myeloma effects of IMiDs, whereas their teratogenic effect is likely to be based on the degradation of SALL4.10 Here, SALL4 is linked to plasma cell myeloma.